Treatment with a γ-ketoaldehyde scavenger prevents working memory deficits in hApoE4 mice

Journal of Alzheimer's Disease

Volumn 27, Issue 1, 2011, Pages 49-59

  Davies, Sean S ^a,b   Bodine, Chris ^a   Matafonova, Elena ^a   Pantazides, Brooke G ^a   Bernoud Hubac, Nathalie ^c   Harrison, Fiona E ^b   Olson, Sandra J ^b   Montine, Thomas J ^d   Amarnath, Venkataraman ^b   Roberts Ii, L Jackson ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Aldehydes; Alzheimer's disease; inflammation; isolevuglandin; oxidative stress; salicylamine; working memory

Indexed keywords

ALDEHYDE; ALDEHYDE DERIVATIVE; APOLIPOPROTEIN E4; GAMMA KETOALDEHYDE; PROSTAGLANDIN SYNTHASE; SALICYLAMINE; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BODY WEIGHT; CEREBELLUM; CONTROLLED STUDY; DEMENTIA; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MALE; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SURVIVAL; WORKING MEMORY;

EID: 80155167219     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-102118     Document Type: Article

References (49)

1. Gu F, Zhu M, Shi J, Hu Y, Zhao Z (2008) Enhanced oxidative stress is an early event during development of Alzheimerlike pathologies in presenilin conditional knock-out mice. Neurosci Lett 440, 44-48.
2. Reich EE, Markesbery WR, Roberts LJ, Swift LL, Morrow JD, Montine TJ (2001) Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am J Pathol 158, 293-297. (Pubitemid 32096495)
3. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ (1998) Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 44, 410-413. (Pubitemid 28421451)
4. Song W-L, Lawson JA, Reilly D, Rokach J, Chang C-T, Giasson B, FitzGerald GA (2008) Neurofurans, novel indices of oxidant stress derived from docosahexaenoic acid. J Biol Chem 283, 6-16.
5. Zhu M, Gu F, Shi J, Hu J, Hu Y, Zhao Z (2008) Increased oxidative stress and astrogliosis responses in conditional double-knockout mice of Alzheimer-like presenilin-1 and presenilin-2. Free Radic Biol Med 45, 1493-1499.
6. Janelsins M, Mastrangelo M, Oddo S, LaFerla F, Federoff H, Bowers W (2005) Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation 2, 23.
7. Yao J, Petanceska SS, Montine TJ, Holtzman DM, Schmidt SD, Parker CA, Callahan MJ, Lipinski WJ, Bisgaier CL, Turner BA, Nixon RA, Martins RN, Ouimet C, Smith JD, Davies P, Laska E, Ehrlich ME, Walker LC, Mathews PM, Gandy S (2004) Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and Fisoprostanes in the absence of detectable amyloid deposits. J Neurochem 90, 1011-1018. (Pubitemid 39099984)
8. Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, Coccia R, Markesbery WR, Butterfield DA (2008) Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis 30, 107-120.
9. LoPachin RM, Gavin T, Petersen DR, Barber DS (2009) Molecular mechanisms of 4-hydroxy-2-nonenal and acrolein toxicity: nucleophilic targets and adduct formation. Chem Res Toxicol 22, 1499-1508.
10. Calingasan NY, Uchida K, Gibson GE (1999) Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J Neurochem 72, 751-756. (Pubitemid 29055239)
11. Mattson MP, Fu W, Waeg G, Uchida K (1997) 4-Hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule-associated protein tau. Neuroreport 8, 2275-2281. (Pubitemid 27319686)
12. Takeda A, Smith MA, Avila J, Nunomura A, Siedlak SL, Zhu X, Perry G, Sayre LM (2000) In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J Neurochem 75, 1234-1241. (Pubitemid 30660513)
13. Davies SS (2008) Modulation of protein function by isoketals and levuglandins. Subcell Biochem 49, 49-70.
14. Zagol-Ikapitte I, Masterson TS, Amarnath V, Montine TJ, Andreasson KI, Boutaud O, Oates JA (2005) Prostaglandin H(2)-derived adducts of proteins correlate with Alzheimer's disease severity. J Neurochem 94, 1140-1145. (Pubitemid 41170600)
15. Davies SS, Brantley EJ, Voziyan PA, Amarnath V, Zagol-Ikapitte I, Boutaud O, Hudson BG, Oates JA, Roberts II LJ (2006) Pyridoxamine analogues scavenge lipid-derived gamma-ketoaldehydes and protect against H(2)O(2)-Mediated Cytotoxicity. Biochemistry 45, 15756-15767. (Pubitemid 46032496)
16. Zagol-Ikapitte I, Matafonova E, Amarnath V, Bodine CL, Boutaud O, Tirona RG, Oates JA, Roberts II LJ, Davies SS (2010) Determination of the pharmacokinetics and oral bioavailability of salicylamine, a potent gamma-ketoaldehyde scavenger, by LC/MS/MS. Pharmaceutics 2, 18-29.
17. Nakajima T, Davies SS, Matafonova E, Potet F, Amarnath V, Tallman KA, Serwa RA, Porter NA, Balser JR, Kupershmidt S, Roberts LJ, 3rd (2010) Selective gamma-ketoaldehyde scavengers protect Nav1.5 from oxidant-induced inactivation. J Mol Cell Cardiol 48, 352-359.
18. Montine KS, Reich E, Neely MD, Sidell KR, Olson SJ, Markesbery WR,Montine TJ (1998) Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. J Neuropathol Exp Neurol 57, 415-425. (Pubitemid 28237325)
19. Mayeux R, Ottman R, Maestre G, Ngai C, Tang MX, Ginsberg H, Chun M, Tycko B, Shelanski M (1995) Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 45, 555-557.
20. Jordan BD, Relkin NR, Ravdin LD, Jacobs AR, Bennett A, Gandy S (1997) Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. JAMA 278, 136-140. (Pubitemid 27287671)
21. Friedman G, Froom P, Sazbon L, Grinblatt I, Shochina M, Tsenter J, Babaey S, Yehuda B, Groswasser Z (1999) Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology 52, 244-248. (Pubitemid 29059046)
22. Lichtman SW, Seliger G, Tycko B, Marder K (2000) Apolipoprotein E and functional recovery from brain injury following postacute rehabilitation. Neurology 55, 1536-1539.
23. Sabo T, Lomnitski L, Nyska A, Beni S, Maronpot RR, Shohami E, Roses AD, Michaelson DM (2000) Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: the allele E3 is neuroprotective whereas E4 increases fatalities. Neuroscience 101, 879-884.
24. Crawford FC, Vanderploeg RD, Freeman MJ, Singh S,Waisman M, Michaels L, Abdullah L,Warden D, LipskyR, Salazar A, Mullan MJ (2002) APOE genotype influences acquisition and recall following traumatic brain injury. Neurology 58, 1115-1118. (Pubitemid 34298559)
25. Bour A, Grootendorst J, Vogel E, Kelche C, Dodart J-C, Bales K, Moreau P-H, Sullivan PM, Mathis C (2008) Middleaged human apoE4 targeted-replacement mice showretention deficits on a wide range of spatial memory tasks. Behav Brain Res 193, 174-182.
26. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 272, 17972-17980. (Pubitemid 27306374)
27. Sullivan PM, Mace BE, Maeda N, Schmechel DE (2004) Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience 124, 725-733. (Pubitemid 38328762)
28. Wang C, Wilson WA, Moore SD, Mace BE, Maeda N, Schmechel DE, Sullivan PM (2005) Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. Neurobiol Dis 18, 390-398. (Pubitemid 40431123)
29. McKhann G, Drachman D, Folstein M, Katzman R, Price D, StadlanEM(1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34, 939-944. (Pubitemid 14076461)
30. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
31. (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The national institute on aging, and reagan institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease. Neurobiol Aging 18, S1-2.
32. Bernoud-Hubac N, Davies SS, Boutaud O, Montine TJ, Roberts LJ2nd (2001) Formation of highly reactive gammaketoaldehydes (neuroketals) as products of the neuroprostane pathway. J Biol Chem 276, 30964-30970.
33. Davies SS, Amarnath V, Brame CJ, Boutaud O, Roberts LJ, 2nd (2007) Measurement of chronic oxidative and inflammatory stress by quantification of isoketal/levuglandin gamma-ketoaldehyde protein adducts using liquid chromatography tandem mass spectrometry. Nat Protoc 2, 2079-2091. (Pubitemid 351565845)
34. Davies SS, Talati M, Wang X, Mernaugh RL, Amarnath V, Fessel J, Meyrick BO, Sheller J, Roberts LJ2nd (2004) Localization of isoketal adducts in vivo using a single-chain antibody. Free Radic Biol Med 36, 1163-1174. (Pubitemid 38479870)
35. Subbanagounder G, Salomon RG, Murthi KK, Brame C, Roberts LJ (1997) Total Synthesis of Iso[4]-levuglandin E2. J Org Chem 62, 7658-7666.
36. Amarnath V, Amarnath K, Matherson T, Davies S, Roberts LJ (2005) A Simplified Synthesis of Diastereomers of Levuglandin E2. Synth Commun 35, 397-408.
37. Costa DA, Cracchiolo JR, Bachstetter AD, Hughes TF, Bales KR, Paul SM, Mervis RF, Arendash GW, Potter H (2007) Enrichment improves cognition in AD mice by amyloidrelated and unrelated mechanisms. Neurobiol Aging 28, 831-844. (Pubitemid 46613825)
38. Diamond DM, Park CR, Heman KL, RoseGM(1999) Exposing rats to a predator impairs spatial working memory in the radial arm water maze. Hippocampus 9, 542-552. (Pubitemid 29509524)
39. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G,Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A[beta] peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985. (Pubitemid 32101645)
40. Davies SS, Amarnath V, Montine KS, Bernoud-Hubac N, Boutaud O, Montine TJ, Roberts LJ, 2nd (2002) Effects of reactive gamma-ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function. FASEB J 16, 715-717.
41. Boutaud O, Montine TJ, Chang L, Klein WL, Oates JA(2006) PGH2-derived levuglandin adducts increase the neurotoxicity of amyloid beta1-42. J Neurochem 96, 917-923.
42. Keller JN, Hanni KB, Markesbery WR (2000) Impaired proteasome function in Alzheimer's disease. J Neurochem 75, 436-439. (Pubitemid 30418211)
43. Cecarini V, Ding Q, Keller JN (2007) Oxidative inactivation of the proteasome in Alzheimer's disease. Free Radic Res 41, 673-680. (Pubitemid 46845588)
44. Brame CJ, Boutaud O, Davies SS,Yang T, Oates JA, Roden D, Roberts LJ, 2nd (2004) Modification of proteins by isoketalcontaining oxidized phospholipids. J Biol Chem 279, 13447-13451. (Pubitemid 38468868)
45. Fukuda K, Davies SS, Nakajima T, Ong BH, Kupershmidt S, Fessel J, Amarnath V, Anderson ME, Boyden PA, Viswanathan PC, Roberts LJ, 2nd, Balser JR (2005) Oxidative mediated lipid peroxidation recapitulates proarrhythmic effects on cardiac sodium channels. Circ Res 97, 1262-1269.
46. Etminan M, Gill S, Samii A (2003) Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327, 128.
47. Lleo A, Galea E, Sastre M (2007) Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell Mol Life Sci 64, 1403-1418. (Pubitemid 46889230)
48. Boutaud O, Andreasson KI, Zagol-Ikapitte I, Oates JA (2005) Cyclooxygenase-dependent lipid-modification of brain proteins. Brain Pathol 15, 139-142. (Pubitemid 40546169)
49. Massaad CA, Washington TM, Pautler RG, Klann E (2009) Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 106, 13576-13581.